BackgroundLowering the diagnostic threshold for troponin is controversial because it may disproportionately increase the diagnosis of myocardial infarction in patients without acute coronary syndrome. We assessed the impact of lowering the diagnostic threshold of troponin on the incidence, management, and outcome of patients with type 2 myocardial infarction or myocardial injury.MethodsConsecutive patients with elevated plasma troponin I concentrations (≥50 ng/L; n = 2929) were classified with type 1 (50%) myocardial infarction, type 2 myocardial infarction or myocardial injury (48%), and type 3 to 5 myocardial infarction (2%) before and after lowering the diagnostic threshold from 200 to 50 ng/L with a sensitive assay. Event-free survival from death and recurrent myocardial infarction was recorded at 1 year.ResultsLowering the threshold increased the diagnosis of type 2 myocardial infarction or myocardial injury more than type 1 myocardial infarction (672 vs 257 additional patients, P < .001). Patients with myocardial injury or type 2 myocardial infarction were at higher risk of death compared with those with type 1 myocardial infarction (37% vs 16%; relative risk [RR], 2.31; 95% confidence interval [CI], 1.98-2.69) but had fewer recurrent myocardial infarctions (4% vs 12%; RR, 0.35; 95% CI, 0.26-0.49). In patients with troponin concentrations 50 to 199 ng/L, lowering the diagnostic threshold was associated with increased healthcare resource use (P < .05) that reduced recurrent myocardial infarction and death for patients with type 1 myocardial infarction (31% vs 20%; RR, 0.64; 95% CI, 0.41-0.99), but not type 2 myocardial infarction or myocardial injury (36% vs 33%; RR, 0.93; 95% CI, 0.75-1.15).ConclusionsAfter implementation of a sensitive troponin assay, the incidence of type 2 myocardial infarction or myocardial injury disproportionately increased and is now as frequent as type 1 myocardial infarction. Outcomes of patients with type 2 myocardial infarction or myocardial injury are poor and do not seem to be modifiable after reclassification despite substantial increases in healthcare resource use.

ObjectiveTo compare basal and reflex tear osmolarity in healthy dogs and to evaluate for correlation among tear film osmolarity, tear production, and tear fern pattern.Animals studiedThe population consisted of 22 healthy adult dogs.ProceduresReflex tear osmolarity was measured in both eyes using the I‐PEN® VET osmometer 30 minutes following the Schirmer tear test (STT‐1) measurement. Subsequently, two minutes following topical anesthetic application, the lacrimal lake and conjunctival fornices were dried, and 3 minutes later, basal tear osmolarity was measured. Tears were extracted from the dye‐free STT‐1 strip by centrifugation, placed on a glass slide, and the ferning pattern was determined by light microscopy. Comparisons between basal and reflex tears were performed with one‐way ANOVA. Correlations between tear osmolarity, STT‐1, and tear ferning were verified by Pearson's correlation coefficient.ResultsNo statistical difference was found between right and left eyes for STT‐1, tear fern pattern, and osmolarity of reflex or basal tears (P < .05). There was no statistical difference between osmolarity of basal and reflex tears among individuals (P < .05). No correlation was detected between tear fern pattern and osmolarity of reflex tears. A weak positive correlation was detected between STT‐1 values and osmolarity of reflex, but not basal tears.ConclusionsThe osmolarity of basal tears did not differ from that of reflex tears. A positive weak correlation exists between tear production and osmolarity of reflex tears. No correlation was detected between tear osmolarity measured by handheld osmometer and tear ferning.

No abstract

Five-amino salicylic acids are recommended for use in the management of inflammatory bowel disease, cardiac complications are a rare although recognised phenomenon. This report aims to highlight this serious but rare adverse reaction. We report here a case of a young man presenting with cardiogenic shock in the context of recent mesalazine treatment in severe ulcerative colitis.